Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: A comparison of a neglected tumour group

British Journal of Cancer

Volumn 113, Issue 12, 2015, Pages 1704-1711

  Vollbrecht, Claudia ^a,d   Werner, Robert ^b   Walter, Robert Fred Henry ^b   Christoph, Daniel Christian ^b   Heukamp, Lukas Carl ^a,f   Peifer, Martin ^c   Hirsch, Burkhard ^d   Burbat, Lina ^d   Mairinger, Thomas ^e   Schmid, Kurt Werner ^b   Wohlschlaeger, Jeremias ^b   Mairinger, Fabian Dominik ^b,d  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

^f Institute of Hematopathology Hamburg   (Germany)

Author keywords

Carcinoids; lung cancer; massive parallel sequencing; NGS; SCLC; targeted sequencing

Indexed keywords

APC PROTEIN; ATM PROTEIN; BETA CATENIN; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; ISOCITRATE DEHYDROGENASE 1; JANUS KINASE 3; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MLH1; PROTEIN P53; PROTEIN RET; PROTEIN TYROSINE PHOSPHATASE SHP 2; SMAD4 PROTEIN; SMOOTHENED PROTEIN; STEM CELL FACTOR; UNCLASSIFIED DRUG; PARAFFIN;

ADULT; AGED; ARTICLE; CARCINOID; CLINICAL ARTICLE; DISTANT METASTASIS; FEMALE; GENE MUTATION; HIGH THROUGHPUT SEQUENCING; HUMAN; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG CANCER; LYMPH NODE METASTASIS; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; NEUROENDOCRINE TUMOR; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PULMONARY NEUROENDOCRINE TUMOR; SMALL CELL LUNG CANCER; COMPARATIVE STUDY; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEUROENDOCRINE TUMORS; PARAFFIN EMBEDDING; YOUNG ADULT;

EID: 84952638616     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.397     Document Type: Article

References (48)

1. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR (2010) A method and server for predicting damaging missense mutations. Nat Methods 7(4): 248-249.
2. Asamura H, Kameya T,Matsuno Y, Noguchi M, Tada H, Ishikawa Y, Yokose T, Jiang SX, Inoue T, Nakagawa K, Tajima K, Nagai K (2006) Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 24(1): 70-76.
3. Beasley MB, Thunnissen FB, Brambilla E, Hasleton P, Steele R, Hammar SP, Colby TV, Sheppard M, Shimosato Y, Koss MN, Falk R, Travis WD (2000) Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 31(10): 1255-1265.
4. Brambilla C, Fievet F, Jeanmart M, de Fraipont F, Lantuejoul S, Frappat V, Ferretti G, Brichon PY, Moro-Sibilot D (2003) Early detection of lung cancer: role of biomarkers. Eur Respir J Suppl 39: 36s-44s.
5. Capodanno A, Boldrini L, Ali G, Pelliccioni S, Mussi A, Fontanini G (2012) Phosphatidylinositol-3-kinase alpha catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours. Oncol Rep 28(5): 1559-1566.
6. Cardillo G, Sera F, Di Martino M, Graziano P, Giunti R, Carbone L, Facciolo F, Martelli M (2004) Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann Thorac Surg 77(5): 1781-1785.
7. Colombo C, Minna E, Rizzetti MG, Romeo P, Lecis D, Persani L, Mondellini P, Pierotti MA, Greco A, Fugazzola L, Borrello MG (2015) The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies. Orphanet J Rare Dis 10: 25.
8. Couce ME, Bautista D, Costa J, Carter D (1999) Analysis of K-ras, N-ras, H-ras, and p53 in lung neuroendocrine neoplasms. Diagn Mol Pathol 8(2): 71-79.
9. Dabir S, Babakoohi S, Kluge A, Morrow JJ, Kresak A, Yang M, MacPherson D, Wildey G, Dowlati A (2014) RET mutation and expression in small-cell lung cancer. J Thorac Oncol 9(9): 1316-1323.
10. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Janne PA (2006) Allelic dilution obscures detection of a biologically significant resistance mutation in EGFRamplified lung cancer. J Clin Invest 116(10): 2695-2706.
11. Engle JA, Kolesar JM (2014) Afatinib: a first-line treatment for selected patients with metastatic non-small-cell lung cancer. Am J Health Syst Pharm 71(22): 1933-1938.
12. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG (1999) Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59(1): 67-70.
13. Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretic L, Seidel D, Zander T, Leenders F, George J, Muller C, Dahmen I, Pinther B, Bosco G, Konrad K, Altmuller J, Nurnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soltermann A, Brustugun OT, Helland A, Solberg S, Lund-Iversen M, Ansen S, Stoelben E, Wright GM, Russell P,Wainer Z, Solomon B, Field JK, Hyde R, Davies MP, Heukamp LC, Petersen I, Perner S, Lovly CM, Cappuzzo F, Travis WD, Wolf J, Vingron M, Brambilla E, Haas SA, Buettner R, Thomas RK (2014) Frequent mutations in chromatinremodelling genes in pulmonary carcinoids. Nat Commun 5: 3518.
14. Fink G, Krelbaum T, Yellin A, Bendayan D, Saute M, Glazer M, Kramer MR (2001) Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 119(6): 1647-1651.
15. Futami H, Egawa S, Takasaki K, Tsukada T, Shiraishi M, Yamaguchi K (2003) Allelic loss of DNA locus of the RET proto-oncogene in small cell lung cancer. Cancer Lett 195(1): 59-65.
16. Garcia-Yuste M, Matilla JM, Cueto A, Paniagua JM, Ramos G, Canizares MA, Muguruza I (2007) Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung. Eur J Cardiothorac Surg 31(2): 192-197.
17. Glubb DM, Cerri E, Giese A, ZhangW, Mirza O, Thompson EE, Chen P, Das S, Jassem J, Rzyman W, Lingen MW, Salgia R, Hirsch FR, Dziadziuszko R, Ballmer-Hofer K, Innocenti F (2011) Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res 17(16): 5257-5267.
18. Karachaliou N, Rosell R (2014) Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. Cancer Biol Med 11(3): 173-181.
19. Krampitz GW, Norton JA (2014) RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Cancer 120(13): 1920-1931.
20. Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding nonsynonymous variants on protein function using the SIFT algorithm. Nat Protoc 4(7): 1073-1081.
21. Leotlela PD, Jauch A, Holtgreve-Grez H, Thakker RV (2003) Genetics of neuroendocrine and carcinoid tumours. Endocr Relat Cancer 10(4): 437-450.
22. Lohmann DR, Fesseler B, Putz B, Reich U, Bohm J, Prauer H, Wunsch PH, Hofler H (1993) Infrequent mutations of the p53 gene in pulmonary carcinoid tumors. Cancer Res 53(23): 5797-5801.
23. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F (2010) Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 26(16): 2069-2070.
24. Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Muller C, Di Cerbo V, Schildhaus HU, Altmuller J, Baessmann I, Becker C, de Wilde B, Vandesompele J, Bohm D, Ansen S, Gabler F, Wilkening I, Heynck S, Heuckmann JM, Lu X, Carter SL, Cibulskis K, Banerji S, Getz G, Park KS, Rauh D, Grutter C, FischerM, Pasqualucci L, Wright G, Wainer Z, Russell P, Petersen I, Chen Y, Stoelben E, Ludwig C, Schnabel P, Hoffmann H, Muley T, Brockmann M, Engel-Riedel W, Muscarella LA, Fazio VM, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman DA, Snijders PJ, Cappuzzo F, Ligorio C, Damiani S, Field J, Solberg S, Brustugun OT, Lund-Iversen M, Sanger J, Clement JH, Soltermann A, Moch H, Weder W, Solomon B, Soria JC, Validire P, Besse B, Brambilla E, Brambilla C, Lantuejoul S, Lorimier P, Schneider PM, Hallek M, Pao W, Meyerson M, Sage J, Shendure J, Schneider R, Buttner R, Wolf J, Nurnberg P, Perner S, Heukamp LC, Brindle PK, Haas S, Thomas RK (2012) Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 44(10): 1104-1110.
25. Pelosi G, Scarpa A, Puppa G, Veronesi G, Spaggiari L, Pasini F, Maisonneuve P, Iannucci A, Arrigoni G, Viale G (2005) Alteration of the E-cadherin/betacatenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids. Cancer 103(6): 1154-1164.
26. Peng L, Song ZG, Jiao SC (2014) Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations. Sci Rep 4: 6104.
27. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T (2001) p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 98(3): 814-822.
28. Przygodzki RM, Finkelstein SD, Langer JC, Swalsky PA, Fishback N, Bakker A, Guinee DG, Koss M, Travis WD (1996) Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol 148(5): 1531-1541.
29. Rea F, Rizzardi G, Zuin A, Marulli G, Nicotra S, Bulf R, Schiavon M, Sartori F (2007) Outcome and surgical strategy in bronchial carcinoid tumours: single institution experience with 252 patients. Eur J Cardiothorac Surg 31(2): 186-191.
30. Rekhtman N (2010) Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med 134(11): 1628-1638.
31. Reva B, Antipin Y, Sander C (2011) Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 39(17): e118.
32. Revannasiddaiah S, Thakur P, Bhardwaj B, Susheela SP, Madabhavi I (2014) Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification. J Thorac Dis 6(Suppl 5): S502-S525.
33. Rindi G, Petrone G, Inzani F (2014) The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. Endocr Pathol 25(2): 186-192.
34. Rotondi M, Ercolino T, Fonte R, Lagonigro MS, Leporati P, Villani L, La Manna L, Mannelli M, Chiovato L (2009) Occurrence of medullary thyroid carcinoma, bronchial carcinoid tumor, and papillary thyroid carcinoma in a family bearing the RET G691S polymorphism. J Endocrinol Invest 32(2): 115-118.
35. Schulte KM, Machens A, Fugazzola L, McGregor A, Diaz-Cano S, Izatt L, Aylwin S, Talat N, Beck-Peccoz P, Dralle H (2010) The clinical spectrum of multiple endocrine neoplasia type 2a caused by the rare intracellular RET mutation S891A. J Clin Endocrinol Metab 95(9): E92-E97.
36. Scott WJ (2003) Surgical treatment of other bronchial tumors. Chest Surg Clin N Am 13(1): 111-128.
37. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3(75): 75ra26.
38. Sos ML, Levin RS, Gordan JD, Oses-Prieto JA, Webber JT, Salt M, Hann B, Burlingame AL, McCormick F, Bandyopadhyay S, Shokat KM (2014) Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Rep 8(4): 1037-1048.
39. Swarts DR, Henfling ME, Van Neste L, van Suylen RJ, Dingemans AM, Dinjens WN, Haesevoets A, Rudelius M, Thunnissen E, Volante M, Van Criekinge W, van Engeland M, Ramaekers FC, Speel EJ (2013) CD44 and OTP are strong prognostic markers for pulmonary carcinoids. Clin Cancer Res 19(8): 2197-2207.
40. Swarts DR, Ramaekers FC, Speel EJ (2012) Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Biochim Biophys Acta 1826(2): 255-271.
41. Takei H, Asamura H, Maeshima A, Suzuki K, Kondo H, Niki T, Yamada T, Tsuchiya R, Matsuno Y (2002) Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 124(2): 285-292.
42. Thomas Jr CF, Tazelaar HD, Jett JR (2001) Typical and atypical pulmonary carcinoids: outcome in patients presenting with regional lymph node involvement. Chest 119(4): 1143-1150.
43. Travis WD (2009) Lung tumours with neuroendocrine differentiation. Eur J Cancer 45(Suppl 1): 251-266.
44. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, Koss MN (1998) Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22(8): 934-944.
45. Travis WD. World Health Organization, International Agency for Research on Cancer, International Association for the Study of Lung Cancer, International Academy of Pathology (2004) Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press Oxford University Press (distributor): Lyon, Oxford.
46. Wang Y, Zheng Y, Zhang W, Yu H, Lou K, Zhang Y, Qin Q, Zhao B, Yang Y, Hui R (2007) Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol 50(8): 760-767.
47. Yeganeh MZ, Sheikholeslami S, Hedayati M (2015) RET proto oncogene mutation detection and medullary thyroid carcinoma prevention. Asian Pac J Cancer Prev 16(6): 2107-2117.
48. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD (2001) Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61(1): 249-255.